VYNE Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for VYNE Therapeutics Inc. (VYNE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are VYNE insiders buying or selling?
VYNE Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 22 Form 4 filings for VYNE: 17 buys ($31.8M) and 5 sells ($9.1M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Jan 16, 2025)
Total Form 4 filings
22
SEC EDGAR
Insider filers
10
Insider buys (17)
$31.8M
Insider sells (5)
$9.1M
Insider sentiment
Net buyingNet insider flow of $22.6M in net buying since January 2018.
Recent VYNE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 16, 2025 | Patrick G Lepore | Director | Purchase | 15.0K | $2.92 | $43.8K | SEC ↗ |
| Nov 17, 2023 | Patrick G Lepore | Director | Purchase | 13.0K | $3.91 | $50.8K | SEC ↗ |
| Mar 22, 2023 | Patrick G Lepore | Director | Purchase | 20.0K | $2.48 | $49.7K | SEC ↗ |
| Mar 22, 2023 | Mutya Harsch | Chief Legal Officer and GC | Purchase | 10.0K | $2.50 | $25.0K | SEC ↗ |
| Dec 2, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $1.02 | $12.7K | SEC ↗ |
| Aug 26, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $1.60 | $20.0K | SEC ↗ |
| Aug 18, 2021 | Joseph Edelman | 10% Owner | Sale | 250.0K | $1.74 | $435.0K | SEC ↗ |
| Aug 17, 2021 | Joseph Edelman | 10% Owner | Sale | 250.0K | $1.84 | $460.0K | SEC ↗ |
| Aug 16, 2021 | Joseph Edelman | 10% Owner | Sale | 338.9K | $2.23 | $755.7K | SEC ↗ |
| May 27, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $3.60 | $45.0K | SEC ↗ |
| May 7, 2021 | Joseph Edelman | 10% Owner | Sale | 1.0M | $3.67 | $3.7M | SEC ↗ |
| Mar 16, 2021 | Patrick G Lepore | Director | Purchase | 12.5K | $7.41 | $92.6K | SEC ↗ |
| Feb 1, 2021 | Joseph Edelman | 10% Owner | Purchase | 4.2M | $2.37 | $10.0M | SEC ↗ |
| Dec 7, 2020 | Patrick G Lepore | Director | Purchase | 50.0K | $1.71 | $85.4K | SEC ↗ |
| Sep 9, 2020 | Andrew Saik | Chief Financial Officer | Purchase | 40.0K | $1.46 | $58.5K | SEC ↗ |
| Sep 9, 2020 | David Domzalski | President and CEO | Purchase | 75.0K | $1.38 | $103.6K | SEC ↗ |
| Jun 11, 2020 | Joseph Edelman | 10% Owner | Purchase | 2.7M | $1.85 | $5.0M | SEC ↗ |
| Jul 26, 2018 | Presidio Partners 2007 GP, L.P. | Other | Sale | 500.0K | $7.65 | $3.8M | SEC ↗ |
| Jan 29, 2018 | venBio Global Strategic Fund II L.P. | 10% Owner | Purchase | 265.0K | $17.00 | $4.5M | SEC ↗ |
| Jan 29, 2018 | Remeditex Ventures LLC | 10% Owner | Purchase | 100.0K | $17.00 | $1.7M | SEC ↗ |
| Jan 29, 2018 | Vivo Capital VIII, LLC | 10% Owner | Purchase | 294.1K | $17.00 | $5.0M | SEC ↗ |
| Jan 29, 2018 | Albert Cha | Director | Purchase | 294.1K | $17.00 | $5.0M | SEC ↗ |
Showing the 22 most recent of 22 Form 4 filings for VYNE Therapeutics Inc..
Most active VYNE insiders
- Patrick G Lepore8 filings
- Joseph Edelman6 filings
- Albert Cha1 filing
- Andrew Saik1 filing
- David Domzalski1 filing
Ask anything about VYNE insider activity
Use Trabud's AI agent to query VYNE Therapeutics Inc.'s Form 4 history in plain English — "Show me VYNE CEO purchases this year" or compare it against any other ticker.
Open the AI agentVYNE insider trading FAQ
Are VYNE Therapeutics Inc. insiders buying or selling?
VYNE Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 22 Form 4 filings for VYNE: 17 buys ($31.8M) and 5 sells ($9.1M). Over the full record that is net buying of $22.6M.
How many insiders trade VYNE stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for VYNE Therapeutics Inc.. The most recent filing was accepted on Jan 16, 2025.
Where does Trabud get VYNE insider trading data?
All VYNE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.